

KURZPROTOKOLL HANNA

Öffentlicher Titel	Nicht-interventionelle Studie mit Nivolumab bei progredienten Kopf-Hals-Tumoren nach platinbasierter Therapie
Wissenschaftl. Titel	Eine nationale, prospektive, nicht-interventionelle Studie (NIS) mit Nivolumab (BMS-936558) bei Patienten mit Plattenepithelkarzinomen im Kopf-Hals-Bereich, die eine Tumorprogression während oder nach einer platinbasierten Therapie aufweisen.
Kurztitel	HANNA
Studienart	multizentrisch, Anwendungsbeobachtung, prospektiv, offen/unverblindet, einarmig, Pharma-Studie, nicht-interventionelle Studie
Studienphase	nicht zutreffend
Erkrankung	KOPF-HALS: Plattenepithelkarzinom: Zweitlinie oder höher
Einschlusskriterien	<ul style="list-style-type: none">- Adult patients (at least 18 years of age at time of treatment decision)- Diagnosis of SCCHN and patients are progressing on or after platinum-based therapy- Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease)- Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in Germany) has already been taken- Patients who provided informed consent to participate in the study
Ausschlusskriterien	<ul style="list-style-type: none">- Patients with a current primary diagnosis of a cancer other than SCCHN, ie, a cancer other than SCCHN that requires systemic or other treatment, or has not been treated curatively (as per discretion of the investigator)- Patients previously treated with nivolumab and/or ipilimumab, an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (applicable for any indication)- Patients currently included in an interventional clinical trial for their SCCHN. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for OS can be enrolled
Alter	18 Jahre und älter
Status	Aktiv
Prüfzentren	Klinikum Darmstadt GmbH Grafenstraße 9 64283 Darmstadt Cora Schwebel-Kottke Tel: 06151 1076670 Fax: 06151 1076676 Onko-Studienzentrum@mail.klinikum-darmstadt.de Universitätsklinikum Gießen und Marburg, Standort Marburg Hämatologie, Onkologie und Immunologie Marburg Nina Marschalek Tel: 06421 58 63546 Fax: 06421 58 62703 studien-onkologie@uni-marburg.de

**KURZPROTOKOLL
HANNA**

Universitätsklinikum Frankfurt

Klinik für Strahlentherapie und Onkologie

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Dr. med. Panagiotis Balermipas

Tel: 069 6301 5130

Fax: 069 6301 5091

panagiotis.balermipas@kgu.de

Sponsor

Bristol-Myers Squibb

**Registrierung in anderen
Studienregistern**

ClinicalTrials.gov NCT03114163